logo

CING

CingulateยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

CING Profile

Cingulate Inc.

A biopharmaceutical company that develops Precision Timed Release platform to treat Attention Deficit Hyperactivity Disorder

Pharmaceutical
12/14/2012
12/08/2021
NASDAQ Stock Exchange
13
12-31
Common stock
1901 W. 47th Place, Kansas City, KS 66205
--
Cingulate Inc., was incorporated in Delaware on December 14, 2012. The Company is a clinical-stage biopharmaceutical company leveraging its proprietary Precision Time-Release (PTR) drug delivery platform technology to build and advance a next-generation drug pipeline designed to improve the lives of patients with common diagnostic diseases. The company's PTR platform incorporates a proprietary Erosion Barrier Layer (EBL) designed to allow the release of APIs at specific, predetermined time intervals, unlocking the potential of once-daily, multi-dose tablets.